## PATH PE Stream Chart Analysis **Current Valuation (Latest Data Point – mid-March 2026):** The latest monthly average price for PATH stands at **$12.45**, which places it in the **Undervalued** zone — below the lowest PE boundary of **27.1 times** (priced at $11.46). Notably, the current price sits just marginally above the PE_stream_1 boundary of $11.46, meaning PATH is trading at a PE multiple slightly above 27.1 times but well below the next boundary of **89.7 times** (priced at $38.01). Given the extremely wide spread between PE bands — ranging from 27.1 times at $11.46 all the way to 340.2 times at $144.19 — the stock is effectively hugging the lowest valuation boundary, suggesting the market is pricing PATH at historically compressed earnings multiples relative to its defined PE range. **Historical Trend Analysis:** PATH's price history reveals a dramatic and prolonged valuation contraction. The stock peaked at approximately **$74.42** in early Q2 2021, representing a period of extreme speculative premium, before entering a steep multi-year decline. By late 2022, the price had collapsed to the **$11–$14** range, a decline of over 80%, reflecting a severe de-rating as growth expectations were reset. A brief recovery emerged through 2023 into early 2024, with prices recovering to the **$22–$25** range around Q1 2024, suggesting a temporary re-rating toward more moderate valuation levels. However, this recovery proved unsustainable — prices retreated sharply again by mid-2024 to the **$11–$13** range, where they have largely remained through early 2026. The PE stream boundaries themselves show a notable structural shift: a significant step-down in the boundary values occurred between Q3 2025 and Q4 2025 (e.g., PE_stream_6 dropping from $12.55 to $144.19 reflects a recalibration of underlying earnings estimates), indicating a meaningful revision in the earnings base used to construct the PE bands. Throughout 2025 and into early 2026, PATH has consistently traded near or just above the lowest PE boundary (27.1 times), signaling persistent market skepticism and a sustained **Undervalued-to-Value** zone positioning — though the highly elevated PE multiples across all bands also reflect the reality that PATH's earnings remain thin, making traditional PE-based valuation frameworks less definitive for this stock.